能谱计算机断层扫描影像特征和尿纤维蛋白原γ链对恶性肺小结节的诊断价值

Value of spectral computed tomography imaging combined with urinary fibrinogen γ chain in diagnosing malignant pulmonary nodules

  • 摘要:
    目的 探讨能谱计算机断层扫描(CT)成像联合尿纤维蛋白原γ链(FGG)在区分良恶性孤立性肺结节(SPN)中的价值。
    方法 选取2018年12月—2021年6月使用能谱CT进行常规双期对比增强扫描的SPN患者63例(37例恶性和26例良性)作为研究对象。能谱CT成像参数包括动脉(ICLa)和静脉(ICLv)期病灶的碘浓度(IC),归一化IC(NICa/NICv,归一化为主动脉中的IC),能谱Hounsfield单位(HU)曲线的斜率(λHUa/λHUv),以及40和70 keV图像上的单色CT数(CT40 keVa/v、CT70 keVa/v)增强。使用酶联免疫吸附试验(ELISA)检测患者的尿FGG水平。通过受试者工作特征(ROC)曲线评估能谱CT成像联合FGG区分良恶性SPN的诊断价值。
    结果 能谱CT成像对恶性结节的诊断准确度为73.0%(27/37),对良性结节的诊断准确度为53.8%(14/26),差异有统计学意义(P < 0.05)。与良性SPN相比,恶性SPN的CT40 keVa、CT40 keVv、CT70 keVa、CT70 keVv、λHUa、λHUv、ICLv均降低,差异有统计学意义(P < 0.05)。恶性SPN患者尿液FGG中位水平为2.210 ng/mL(IQR:1.780~3.120 ng/mL),良性SPN患者尿液FGG中位水平为1.587 ng/mL(IQR:1.140~1.975 ng/mL),差异有统计学意义(z=4.264,P=0.014)。尿液FGG对恶性结节的诊断准确度为73.0%(27/37),对良性结节的诊断准确度为46.2%(12/26),差异有统计学意义(P < 0.05)。能谱CT成像和FGG联合鉴别良恶性SPN的曲线下面积(AUC)为0.924,敏感度为93.8%,特异度为85.7%。
    结论 能谱CT成像联合尿液FGG水平检测有利于提高良性和恶性SPN的鉴别诊断效率。

     

    Abstract:
    Objective To investigate the value of spectral computed tomography (CT) imaging combined with urinary fibrinogen γ chain (FGG) in differentiating benign and malignant solitary pulmonary nodules (SPN).
    Methods From December 2018 to June 2021, a total of 63 (37 malignant and 26 benign) patients with SPN who underwent conventional dual-phase contrast-enhanced scanning using spectral CT were selected as study subjects. The parameters of energy spectrum CT imaging included iodine concentration (IC) of arterial (ICLa) and venous (ICLv) stage lesions; normalized IC (NICa/NICv, normalized to IC in aorta); slope of Hounsfield unit (HU) curve of energy spectrum (λHUa/λHUv) and the monochrome CT number (CT40 keva/v, CT70 keva/v) on 40 and 70 keV images were enhanced. Urinary FGG levels were measured using enzyme-linked immunosorbent assay (ELISA). The diagnostic value of energy spectrum CT imaging combined with FGG in differentiating benign and malignant SPN was evaluated by receiver operating characteristic (ROC) curve.
    Results The diagnostic accuracy of energy spectrum CT imaging for malignant nodules was 73.0%(27/37), and was 53.8% (14/26) for benign nodules, the difference was statistically significant (P < 0.05). The diagnostic accuracy of spectral CT imaging for malignant nodules was 73.0%(27/37), and the diagnostic accuracy for benign nodules was 53.8% (14/26), and the difference was statistically significant (P < 0.05). Compared with benign SPN, the CT40 keVa, CT40 keVv, CT70 keVa, CT70 keVv, λHUa, λHUv and ICLv of malignant SPN were significantly decreased (P < 0.05). The median urine FGG level of patients with malignant SPN was 2.210 ng/mL (IQR, 1.780 to 3.120 ng/mL), and was 1.587 ng/mL (IQR, 1.140 to 1.975 ng/mL) in patients with benign SPN, the difference was statistically significant (z=4.264, P=0.014). The diagnostic accuracy of urine FGG for malignant nodules was 73.0% (27/37), and 46.2% (12/26) for benign nodules, the difference was statistically significant (P < 0.05). The area under the curve (AUC), sensitivity and specificity were 0.924, 93.8% and 85.7% for the differentiation of benign and malignant SPN by energy spectrum CT and FGG.
    Conclusion Energy spectrum CT imaging combined with urine FGG level detection is beneficial to improve the differential diagnosis efficiency of benign and malignant SPN.

     

/

返回文章
返回